Please try another search
Q BioMed Inc., a biomedical acceleration and development company, focuses on licensing, acquiring, and providing resources to life sciences and healthcare companies. The company offers Strontium Chloride Sr-89 and Metastron, a radiopharmaceutical therapeutic for the treatment of metastatic bone cancer pain. It is also developing Man-01, that is used for the treatment of primary open angle glaucoma; QBM-001 for rare pediatric non-verbal autism spectrum disorder; and Uttroside-B, a novel chemotherapeutic for liver cancer. Q BioMed Inc. has a partnership with Mannin Research Inc. for the development of therapeutic drugs to treat acute respiratory distress syndrome, glaucoma, kidney diseases, and others. The company was formerly known as ISMO Tech Solutions, Inc. and changed its name to Q BioMed Inc. in July 2015. Q BioMed Inc. was incorporated in 2013 and is based in New York, New York.
Name | Age | Since | Title |
---|---|---|---|
Pamela Ventola | - | 2019 | Member of Advisory Board |
George N. Nikopoulos | - | 2015 | Member of Advisory Board |
Denis D. Corin | 51 | 2015 | Chairman, CEO & President |
Rajendra Apte | - | 2018 | Member of Advisory Board |
Pamela Ventola | - | 2019 | Member of Advisory Board |
Heather Sheardown | - | - | Member of Advisory Board |
William S. Rosenstadt | 56 | 2015 | Chief Legal Officer, General Counsel & Director |
Riccardo Panicucci | 62 | 2017 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review